RAINBOW-Asia: A randomized, multicenter, double-blind, phase III study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line chemotherapy with platinum and fluoropyrimidine.

Rui Hua Xu,Yanqiao Zhang,Hongming Pan,Ji-Feng Feng,Tao Zhang,Tianshu Liu,Yanru Qin,Rubing Han,Wanli Zhang,Lin Shen

RAINBOW-Asia: A randomized, multicenter, double-blind, phase III study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line chemotherapy with platinum and fluoropyrimidine.

2021

Rui Hua Xu
Yanqiao Zhang
Hongming Pan
Ji-Feng Feng
Tao Zhang
Tianshu Liu
Yanru Qin
Rubing Han
Wanli Zhang
Lin Shen

199Background: Ramucirumab (RAM), a fully human IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor 2, has been approved in combination with paclitaxel (PTX) in patients ...

Keywords:

Medicine
Kinase insert domain receptor
Oncology
Paclitaxel
Internal medicine
Monoclonal antibody
Ramucirumab
Placebo
double blind
first line chemotherapy
Adenocarcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations